ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of “Buy” from Analysts
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has received an average recommendation of “Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Nine research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued a report on the stock in […]
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has received an average recommendation of “Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Nine research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued a report on the stock in […]
